Latest Breaking News On - Peking university cancer - Page 1 : comparemela.com

Share this article Share this article BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/  Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial in China to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of its anti-CTLA4 monoclonal antibody (YH001) in patients with solid tumors. In May 2020, Eucure Biopharma initiated a first-in-human Phase I dose-escalation trial of YH001 in advanced solid tumors in Australia. One run-in cycle was used to explore the safety and tolerability of escalating doses of YH001 monotherapy, followed by four treatment cycles of YH001 in combination with fixed dose Toripalimab (an anti-PD-1 antibody). In the first four cohorts, no grade 3 or higher adverse events (AE) were observed, demonstrating a favorable safety profile.

United statesYuanyuan liBiocytogen eucure biopharmaYuelei shenEucure biopharmaDepartment of oncology at shanghai pulmonary hospitalProfessor cai cun zhouShanghai pulmonaryProfessor yongsheng wangWest china hospitalPeking university cancerஒன்றுபட்டது மாநிலங்களில்யுனிுான் லிதுறை ஆஃப் புற்றுநோயியல் இல் ஷாங்காய் நுரையீரல் மருத்துவமனைப்ரொஃபெஸர் காய் கன் ஜூஷாங்காய் நுரையீரல்